PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Starting Regimen Predicts Early ADHD Treatment Instability in Adults

methylphenidateatomoxetineguanfacineADHDadult ADHDpolytherapyclaims databasepharmacoepidemiologymedication persistencecompeting riskFine-GrayJapan Psychiatry / Psychopharmacology

Background Information

ADHD treatment choice influences medication stability in Japanese adults.

Understanding medication regimen changes in adults with attention-deficit/hyperactivity disorder (ADHD) can help improve treatment strategies and adherence. The study found that initial polytherapy had a higher instability rate compared to methylphenidate alone, with a subdistribution hazard ratio of 2.65. The findings highlight significant differences in regimen stability among ADHD treatments, indicating the need for careful selection and monitoring of therapy in practice. Initial ADHD medication choice affects treatment stability, with polytherapy showing higher instability.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Yonezawa N, Momo K

Citation: Yonezawa N, Momo K Real-World Medication Regimen Change in Adults with ADHD: A Large Claims Database Study. Biological & pharmaceutical bulletin. 2026;49(8):1263-1270. doi:10.1248/bpb.b26-00127

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →